Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Oncology Medical Homes: ASCO-Community Oncology Alliance Standards.
Journal: JCO oncology practice
Published: July 21, 2025
Overlooked Risk in Cancer Care: Failure of Medical Reconciliation.
Journal: JCO oncology practice
Published: June 24, 2025
Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 19, 2025
Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards.
Journal: Oncology nursing forum
Published: July 01, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2024
Supportive Care for Cancer Patients Via Telehealth: Breaking Bad News and Providing Palliative Care Virtually.
Journal: Cancer journal (Sudbury, Mass.)
Published: January 24, 2024
Physician Disruptive Behavior Compromising Safe Care Delivery.
Journal: JCO oncology practice
Published: January 04, 2024
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
Journal: JCO oncology practice
Published: November 03, 2023
Uncovering the Risks of Anticancer Therapy Through Incident Report Analysis Using a Newly Developed Medical Oncology Incident Taxonomy.
Journal: Journal of patient safety
Published: November 03, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 29, 2023
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Journal: NPJ breast cancer
Published: August 25, 2023
Last Updated: 09/26/2026